B-cell Activating Factor (BAFF), also known as B Lymphocyte Stimulator (BLyS), is a crucial cytokine in the tumor necrosis factor (TNF) ligand family. It plays a significant role in the survival, proliferation, and differentiation of B cells. BAFF is encoded by the TNFSF13B gene and is also referred to by several other names, including CD257, TALL-1, and THANK .
BAFF is a 285-amino acid long peptide glycoprotein that undergoes glycosylation at residue 124 . It is expressed by various cell types, including monocytes, macrophages, dendritic cells, and B cells. The cytokine binds to three receptors: TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFF-R) . These interactions are critical for B cell activation and function.
BAFF is essential for the maintenance of B cell homeostasis and the regulation of immune responses. It induces B cell proliferation and immunoglobulin secretion, acting as a survival factor for immature, naive, and activated B cells . Elevated levels of BAFF are associated with autoimmune diseases and various hematological malignancies .
Recombinant BAFF (Human) can be produced in various systems, including plants. Plant-based expression systems offer several advantages, such as cost-effectiveness, scalability, and reduced risk of contamination with human pathogens . The recombinant protein retains its biological activity and can be used in research and therapeutic applications.
BAFF-targeted therapies are being explored for the treatment of autoimmune diseases and B-cell malignancies. Monoclonal antibodies like belimumab, atacicept, and tabalumab have shown promise in clinical trials . These therapies aim to modulate BAFF levels and its interactions with receptors to achieve therapeutic benefits.